Ernexa Therapeutics (ERNAW) EPS (Weighted Average and Diluted) (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported EPS (Weighted Average and Diluted) of -$6.95 for Q1 2026, up 87.97% on a YoY basis from -$3.7 in Q1 2025, and down 69400.0% quarter-over-quarter from -$0.01 in Q4 2025.
Ernexa Therapeutics (ERNAW) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at -$6.95 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 87.97% year-over-year to -$6.95; the trailing twelve-month figure through Mar 2026 stood at -$7.72 (up 91.26% YoY), and the FY2025 full-year result was -$2.24, up 95.42% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$6.95, down from -$0.01 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $58.49 in Q4 2024, with the low at -$73.7 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$6.44 across 5 years, with a median of -$1.14 in 2023.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 5230.7% in 2024 against a maximum downside of 7055.34% in 2024.
- Ernexa Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.02 in 2022, then declined by 11.76% to -$1.14 in 2023, then soared by 5230.7% to $58.49 in 2024, then sank by 100.02% to -$0.01 in 2025, then sank by 69400.0% to -$6.95 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$6.95 (Q1 2026), -$0.01 (Q4 2025), and -$0.15 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ernexa Therapeutics | - | - | - | -6.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.95 |
| Dec 31, 2025 | -0.01 |
| Sep 30, 2025 | -0.15 |
| Jun 30, 2025 | -0.61 |
| Mar 31, 2025 | -57.76 |
| Dec 31, 2024 | 58.49 |
| Sep 30, 2024 | -73.70 |
| Jun 30, 2024 | -15.34 |
| Mar 31, 2024 | -1.23 |
| Dec 31, 2023 | -1.14 |
| Sep 30, 2023 | -1.03 |
| Jun 30, 2023 | -0.85 |
| Mar 31, 2023 | -1.06 |
| Dec 31, 2022 | -1.02 |
| Sep 30, 2022 | -2.49 |
| Jun 30, 2022 | -1.16 |
| Mar 31, 2022 | -3.50 |
| Dec 31, 2021 | 0.18 |
| Sep 30, 2021 | -34.03 |
| Jun 30, 2021 | -0.24 |